A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
A phase 1/2 trial of LBL-024 for Injection in advanced solid tumours, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.
Overview
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT05170958 by Nanjing Leads Biolabs Co.,Ltd, with 396 participants planned, started 2022-01-06 and due to reach its primary completion in 2026-12. Interventions recorded: LBL-024 for Injection.
Similar pages
not linked directly; found by shared links- TrialA Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Shares Nanjing Leads Biolabs and the tag pipeline.
- TrialA Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
Shares Nanjing Leads Biolabs and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.